<bill session="116" type="s" number="1209" updated="2022-11-01T19:47:17Z">
  <state datetime="2019-04-11">REFERRED</state>
  <status>
    <introduced datetime="2019-04-11"/>
  </status>
  <introduced datetime="2019-04-11"/>
  <titles>
    <title type="display">REMEDY Act</title>
    <title type="short" as="introduced">Reforming Evergreening and Manipulation that Extends Drug Years Act</title>
    <title type="short" as="introduced">REMEDY Act</title>
    <title type="official" as="introduced">A bill to amend the Federal Food, Drug, and Cosmetic Act with respect to approval of abbreviated new drug applications.</title>
  </titles>
  <sponsor bioguide_id="C001075"/>
  <cosponsors>
    <cosponsor bioguide_id="C001096" joined="2019-05-16"/>
    <cosponsor bioguide_id="D000563" joined="2019-04-11"/>
    <cosponsor bioguide_id="M001176" joined="2019-07-30"/>
    <cosponsor bioguide_id="M001153" joined="2019-05-15"/>
    <cosponsor bioguide_id="P000595" joined="2019-09-25"/>
    <cosponsor bioguide_id="S001181" joined="2019-06-05"/>
    <cosponsor bioguide_id="S001203" joined="2019-05-22"/>
  </cosponsors>
  <actions>
    <action datetime="2019-04-11">
      <text>Introduced in Senate</text>
    </action>
    <action datetime="2019-04-11" state="REFERRED">
      <text>Read twice and referred to the Committee on Health, Education, Labor, and Pensions.</text>
    </action>
  </actions>
  <committees>
    <committee code="SSHR" name="Senate Health, Education, Labor, and Pensions" subcommittee="" activity="Referral"/>
  </committees>
  <relatedbills>
    <bill session="116" type="h" number="3812" relation="identical"/>
  </relatedbills>
  <subjects>
    <term name="Health"/>
    <term name="Drug safety, medical device, and laboratory regulation"/>
    <term name="Intellectual property"/>
    <term name="Prescription drugs"/>
  </subjects>
  <amendments/>
  <summary date="2021-09-13T15:42:50Z" status="Introduced in Senate">Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act 

This bill addresses drug patents with respect to Food and Drug Administration (FDA) approval of a drug application.

Currently, when the owner of a brand-name drug approval sues a generic drug company for patent infringement based on the generic company's application for FDA approval of a generic version of the brand-name drug, there is generally a 30-month stay on the approval of the generic version. Under this bill, the stay goes into effect only if the lawsuit alleges infringement of a patent that claims the drug compound.

When the U.S. Patent and Trademark Office invalidates a patent for a drug, the FDA must update its list of relevant patents for the drug.</summary>
</bill>
